NeoGenomics Q2 FY26 adjusted EBITDA climbs 36% to $14 million; revenue rises 11% to $202 million

Reuters2026/07/28 20:09

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeoGenomics posted Q2 2026 revenue of $202 million, up 11% year over year.
Adjusted EBITDA climbed 36% to $14 million, lifting adjusted EBITDA margin 130 basis points to 7.2%.
Operating expense fell 3% to $102 million; period-end cash totaled $146 million following $20 million of operating cash flow.
NGS revenue rose 26% year over year on 14% higher volume; clinical volume increased 2% to 363,000 tests.
Raised full-year 2026 revenue guidance to $802-$806 million, projecting adjusted EBITDA of $56-$58 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeoGenomics Q2 FY26 adjusted EBITDA climbs 36% to $14 million; revenue rises 11% to $202 million

You may also like

Crypto prices